Haploidentical donors are available for most patients who need allografts but do not have matched donors. However, GVHD, rejection, delayed immune reconstitution, and infections have been significant barriers. We designed a haploidentical BMT protocol focusing on prevention of GVHD and rejection. A total of 53 leukemic patients underwent haploidentical G-CSF-primed BMT without ex vivo T-cell depletion. GVHD prophylaxis consisted of antithymocyte globulin, cyclosporine, methotrexate, and mycophenolate mofetil. In all, 38 patients (the CD25 group) received additional anti-CD25 monoclonal antibody basiliximab. The results were compared to 15 patients who did not receive basiliximab. All patients achieved trilineage engraftment with full-donor chimerism. The incidence of acute II-IV GVHD was 11% in the CD25 group vs 33% in the control group (P ¼ 0.046). The overall incidence of extensive chronic GVHD was 15%. T, B, and NK cells recovered within 12 months post transplant. The disease-free survival at 2 years was 53% with a median follow-up of 31 months. In conclusion, G-CSF primed haploidentical BMT along with sequential immunosuppressive agents as described here deserves further study.
HLA-matched allogeneic hematopoietic stem cell transplant (HSCT) is limited by the availability of matchedrelated or unrelated donors. Haploidentical HSCT is available readily to almost all patients who need allogeneic HSCT. 1 However, the high incidence of GVHD and graft failure/rejection make the procedure risky. 2, 3 Intensified conditioning to prevent graft rejection and eradicate leukemia is associated with increased regimen-related toxicity and greater incidence of acute GVHD. 4, 5 Vigorous ex vivo T-cell depletion (TCD) decreases GVHD but results in increased graft rejection and delayed immune reconstitution. [6] [7] [8] We designed a haploidentical HSCT protocol without ex vivo TCD based on the knowledge that marrow contains 10 times fewer mature T cells than blood 9 and G-CSF donor priming enhances engraftment and reduces the incidence of acute GVHD. 10, 11 The use of this strategy in matched sibling transplants resulted in an incidence of acute GVHD that was 6.3-10.5%. 10, 11 We then extended the study to mismatched-related donors and developed the current haplo-BMT protocol. In the initial phase during February 1999 and November 2000, 15 patients with high-risk hematological malignancies underwent haploidentical G-CSF primed marrow transplants. Nine patients survived more than 1 year. 12 Three patients died of acute GVHD. We then modified the protocol with the addition of an anti-CD25 monoclonal antibody to prevent both rejection and GVHD. Since November 2000, 38 more patients with hematological malignancies have been transplanted from haploidentical donors.
Materials and methods

Patients and donors
Between November 2000 and September 2002, 38 consecutive patients with leukemia who needed urgent transplants but had no HLA-matched or one antigen mismatched donor available underwent unmanipulated haploidentical BMT. All patients had one or more of the following high-risk factors and/or poor prognosis indicators: acute leukemia CR1 with high risk of relapse (more than two induction therapies with residual leukemia cells), induction therapy needed for more than 5 months, acute leukemia in CR2 or above, failed to achieve remission after two standard induction therapies, chemotherapy-resistant disease, CML in chronic phase for more than 2 years, or CML in accelerated phase or in blast phase. All patients were enrolled from the Air Force General Hospital (AFGH) after discussion of potential risks and benefits of the study. The Institutional Review Board (IRB) at the AFGH approved the study protocol and consent forms. All patients and donors were provided written informed consents. All donors were HLA-haploidentical relatives with at least two MHC antigen mismatches with the recipients by polymerase chain reaction sequence-specific primers (PCR-SSP) and high-resolution molecular genetic typing. Table 1 summarizes patient characteristics and clinical results of these 38 patients who were transplanted after November 2000 with anti-CD25 monoclonal antibody and 15 patients who were transplanted before November 2000 without anti-CD25.
Transplant procedure
Donors were primed with G-CSF (Lenograstim, Chugai Pharmaceutical Co, Tokyo, Japan) at 3-4 mg/kg/day single daily subcutaneous injections for seven consecutive days as previously described. [10] [11] Bone marrow cells were harvested from the posterior iliac crests on the eighth day with a target volume collection of 15-20 ml/kg recipient body weight, and were infused fresh and unmanipulated on the same day (day 0). All patients received a uniform conditioning regimen including cytarabine 3 g/m 2 /day i.v. in two divided doses (3 h per infusion) on days -7, -6, and -5, cyclophosphamide 45 mg/kg/day on days -5 and -4, and 1000 cGy TBI from a high-energy linear accelerator in two fractions on days -2 and -1 at a rate of 5-6 cGy/min.
Moulded lead lung shields were used to limit the corrected mean total lung dose to 750 cGy. Antithymocyte globulin (ATG; Fresenius AG, Oberurse, Germany), cyclosporine (CsA), methotrexate (MTX), mycophenolate mofetil (MMF), and anti-CD25 monoclonal antibody (basiliximab, Novartis Pharma AG, Basle, Switzerland) were used for GVHD prophylaxis. From day -4 to -1, ATG 5 mg/kg was infused daily over 8 h. CsA was given as a continuous i.v. infusion at 1.5 mg/kg/day from day -7 to -1, the dose was increased to 3 mg/kg/day from day 0 until bowel function recovered, and then switched to the oral route at 5 mg/kg/ day in two divided doses. From day þ 180, if there was no chronic GVHD, the CsA dose was reduced by 5% every week and stopped by day þ 360. The CsA dose was reduced if the trough level was over 300 ng/ml or the serum creatinine level exceeded 2 mg/dl. MTX was given at 15 mg/m 2 on day þ 1, then 10 mg/m 2 on day þ 3, þ 6, and þ 11. MMF was administered at 1 g/day in two divided doses from day þ 7 to þ 100. Over 30 min, two 20 mg doses of basiliximab were administered i.v.; on day 0 (2 h before marrow infusion) and on day þ 4. 13 The diagnosis and grading of GVHD was established according to previously defined critera. 14 
Assessment of engraftment, chimerism, and immune reconstitution
The day of engraftment was the first of three consecutive days with ANC 40.5 Â 10 9 /l. Platelet engraftment was defined as a platelet count 420 Â 10 9 /l with no requirement Table 1 Comparison of patient and donor characteristics between the groups with and without anti-CD25 monoclonal antibody treatment 
Cytomegalovirus (CMV) prophylaxis and treatment
All patients received prophylactic ganciclovir 5 mg/kg twice a day from days -9 to -2. 15 Patients were then monitored weekly with CMV pp65 assay. If positive, the patients were given pre-emptive treatment with ganciclovir 5 mg/kg twice a day for 2 weeks, then 5 mg/kg once a day until pp65 became negative. 16 If patients were persistently pp65 positive after a 3-month treatment course, no further CMV treatment was given unless clinical evidence of CMV disease appeared. When ANC declined to o1 Â 10 9 /l and/or platelets to o25 Â 10 9 /l, ganciclovir was changed to foscarnet.
Statistical analysis
Evaluations were based on data available by August 15, 2004 and final data analysis included engraftment, incidence of acute and chronic GVHD, immune reconstitution, and probability of survival. Patients who survived 6 months or longer were evaluated for chronic GVHD. Patients who were alive at final analysis were censored on the date of the last follow-up. w 2 Statistics were used to compare categorical variables of the donors, recipients, and underlying diseases. The cumulative incidence for platelet engraftment and acute GVHD was calculated. Probability of survival was estimated by the Kaplan-Meier method. Log rank tests were used for univariate comparisons. Table 1 shows that the CD25 and control groups were comparable in terms of patient characteristics. Trilineage engraftment was seen in all patients, with median time to ANC and platelet recovery of 19 days (range, 13-24) and 22 days (range, 16-32), respectively. Six patients died before day 100. Of the patients, 24 of the remaining 32 had platelet counts 4100 Â 10 9 /l by day þ 100. Full donor-type chimerism (495%) was seen 1 month post transplant amongst all patients. The patients who remained diseasefree maintained full donor-type chimerism over 24-45 months.
Results
Four of 38 patients in CD25 group developed grade II-IV acute GVHD. The incidence of grade II-IV acute GVHD was 10.5%. Five of 15 patients who were transplanted without anti-CD25 developed grade II-IV acute GVHD (33.3%). There was a significant difference between the CD25 vs non-CD25 groups (P ¼ 0.046) ( Table 2 and Figure 1) . Three of 15 patients in control group and three of 38 in CD25 group died of severe acute GVHD. The incidence of grade II-IV acute GVHD was 5.9% in twoantigen HLA mismatch and 14.3% in three-antigen HLA mismatch. The difference did not achieve a statistical significance. In all, 26 patients who survived over 6 months in CD25 group were evaluated for chronic GVHD. Of the 26 patients, 23 developed chronic GVHD including four with extensive chronic GVHD involving more than two organ/systems. Nine patients survived over 6 months in non-CD25 control group. All nine patients developed chronic GVHD including two with extensive disease and one died of chronic GVHD. There was no statistically significant difference in chronic GVHD between the CD25 and non-CD25 groups (Table 2) . Haplo BMT, CD25 mAb, GVHD, hematological malignancy S-Q Ji et al CD19 þ B cells, and CD16 þ /CD56 þ NK cells recovered rather rapidly to normal levels within 6-12 months post transplant. Absolute CD3 þ CD4 þ cell counts recovered above 200/ml within 6 months and returned to normal in 18 months.
Immune reconstitution
Survival and clinical outcomes
Follow-up lasted more than 2 years in all patients with a median of 31 months (range 24-45 months). In all, 28 of the 38 patients are alive in complete remission with Karnofsky performances 490%. The actual survival rate of this group at 2 years was 52.6%. In all, 12 patients died of transplant-related complications: GVHD (n ¼ 3), CMV pneumonitis (n ¼ 2), fungal infections (n ¼ 2), bacterial infections (n ¼ 2), viral hepatitis (n ¼ 1), thrombotic microangiopathy (n ¼ 1), and heart failure (n ¼ 1). Six patients died from disease recurrence. Patients who were transplanted at the relapse state had significantly lower survival rates (27.2%) compared to the patients who were transplanted in remission states (62.8%) (P ¼ 0.043) (Figure 2 ).
Discussion
Our study shows a low incidence of acute GVHD after haploidentical BMT with the addition of anti-CD25 monoclonal antibody when compared to the published literature. [17] [18] [19] [20] There are several possible explanations. First, G-CSF primed marrow rather than G-CSF-mobilized PBSCs was used to facilitate engraftment and to reduce mature donor T cells in the grafts. Besinger et al, 21 compared G-CSF-mobilized PBSCs to historically steadystate marrow transplants. G-CSF mobilized PBSCs had faster engraftment and a similar incidence of GVHD, although T cell numbers in the G-CSF mobilized PBSCs were often 10 times higher than in the marrow. 9, 21 Comparison of the outcome of the HLA-identical marrow transplants with and without donor G-CSF priming in a homogenous group of CML patients showed the G-CSF primed marrow transplants engrafted faster with a lower incidence of grade II-IV acute GVHD, only 6.3% compared to 33% in the steady-state marrow transplants. 11 Furthermore, G-CSF reduced lymphocytes in the marrow and modulated subsets of T cells resulting in a significantly decreased CD4/CD8 ratio. Although it is somewhat controversial as to how G-CSF modulates T cells and exactly what type T cells are responsible for GVHD. 22 It is known that cytokines produced by CD4 þ and CD8 þ T cells can be characterized into two patterns, Th1 (IL-2 and interferon-gamma) and Th2 responses (IL-4 and IL-10).
23
Th1-type responses are critical for acute GVHD and treatment that induces the Th2 response reduces GVHD. 24, 25 G-CSF polarizes T-cell differentiation from Th1-to Th2-type cells and induces Th2 responses with production of IL-4 and IL-10. 26, 27 Second, GVHD prophylaxis with sequential immunosuppressant agents is crucial in haploidentical BMT, especially without ex vivo TCD. We believe that major reactions of both GVHD and host-versus-graft rejection (HVGR) are occurring during the initial phase of the transplant. 5 Pathogenesis of acute and chronic GVHD is a dynamic course and each stage has its major pathogenic offenders during development of the disease. 5, 24, 28 Our strategy focused on the dynamic course of GVHD using different agents to block major offenders at different stages to prevent the cascade effect of GVHD. We chose CsA and MTX as a baseline and added different immunosuppressant agents at different stages of the transplant course with an emphasis on up-front prevention. ATG (half-life 2 weeks) was given on days -4 to -1 to suppress and/or deplete host lymphocytes to prevent HVGR as well as to suppress/deplete infused donor lymphocytes in vivo to prevent GVHD. MMF as a purine analog is a powerful inhibitor of lymphocyte proliferation. We added MMF on day þ 7 to prevent rapid proliferation of donor Table 3 Immune reconstitutions of lymphocyte subsets and mean of absolute cell numbers/ul (range) 15 30 45
Non-relapse group (n =27, 62.8%)
Relapse group (n =11, 27.2%) lymphocytes at this stage. The combination of CsA þ MMF showed a more potent immunosuppressive effect in preventing graft rejection than CsA þ MTX. 29 In the current study we added a new immunosuppressant, anti-CD25 mAb Basiliximab, which binds specifically to IL-2 receptor-a (IL-2Ra) of activated T cells with high affinity and is a potent inhibitor of IL-2 mediated T-cell activation and proliferation. In contrast, resting T cells, which do not express IL-2Ra, are not affected. 13 A preclinical study has demonstrated that allospecific TCD by using an immunotoxin, directed against the a chain of IL-2 receptor, was feasible and specific. 30 TCD with anti-CD 25 mAbs was effective in preventing both graft rejection and GVHD in a murine model with complete haplotype mismatched hematopoietic stem cell transplants. 31 It competes effectively with IL-2 and inhibits IL-2 driven proliferative responses. 32 However, there are several forms of anti-CD25 mAb and each carries a different biological profile. Martin et al, reported a higher incidence of GVHD using a CD25-specific immunotoxin for prevention of GVHD in a matched unrelated transplant setting. The anti-CD25 product and dose course in that study was very different from our study as was the transplant protocol and graft source. 33 Compared to other anti-CD25 mAbs, Basiliximab has a longer mean terminal half-life (4-6 weeks), minimal immunogenicity, and lacks the problem of toxicity that makes it potentially a valuable new agent for immunoprophylaxis. 34 We have demonstrated that CD25 mAb eliminated donor-specific alloreactive T cells. 35 Of the subsequent 38 patients, only four developed grade II-IV acute GVHD. The other potential explanation for the low incidence of severe GVHD was the relative young age, median age 17 years (range 6-44), and inherent CMV negativity as almost 50% of patients were CMV negative.
Although GVHD is associated with GVL, the two may be separable. 36, 37 Matched-unrelated donor (MUD) HSCT had relatively lower relapse rates in high-risk patients than matched-related BMT without evidence of clinical GVHD suggesting that a minor antigen mismatch might contribute to GVL effect without causing clinical GVHD. Therefore, proper immune system reconstitution after allogeneic HSCT becomes another crucial factor in determining risk of infection and disease relapse. Our protocol did not use any ex vivo TCD. All immune system reconstitutions were 6-18 months faster than that reported by many other studies. 8, [36] [37] [38] [39] Disease recurrence after any type of treatment is associated with disease status/classification. Our data again confirmed that patients who were in remission had the best outcome and patients who were in relapse or CML blast phase had the worst outcome with 2-year actuarial survival probabilities of 27.2% compared to 62.8% in nonrelapse.
As our current study contained a relatively small number of patients, a larger, multicenter study with more patients and longer follow-up is warranted.
